Omakase, with the collaboration of Bristol Myers-Squibb, has released the third volume of Omakase’s Lab report series: “The Burden of Cancer in Spain”. In this report, Omakase has analysed the impact of cancer in Spain for the year 2015 by analysing its epidemiological burden, formed by the prevalence at 5 years (cancer cases), the incidence (new cases of cancer), mortality and inability; and its economic burden, consisting of direct costs (costs of using SNS resources), indirect costs (costs of productivity loss) and intangible costs (years of healthy life lost due to cancer).
Omakase, with the collaboration of Bristol Myers-Squibb, has created a specific Multi-Criteria Decision Analysis manual for patients. The objective of this manual is to enable patients to participate, either individually or collectively, in the evaluation processes of health technologies, by providing them with a tool (Multi-Criteria Decision Analysis) that allows them to understand and structure key information for the defence of their interests.
In this report we identify the P&R situation in Spain of ODs approved by the European Commission between 2012-2016, and we analyse potential favourable ODs profiles for P&R approval in Spain, based on clinical, economic and institutional reimbursement variables.